Research: Letrozole Protocol

Nature Communications · March 2026

Modified letrozole vs GnRH antagonist protocols in ovarian aging women for IVF: an open-label, multicenter, randomized controlled trial

Read paper

TL;DR In 318 women with DOR or age 40–45, modified letrozole (mLP) matched the standard GnRH-antagonist protocol on overall pregnancy and live birth rates — using less drug over fewer stim days. In one DOR subgroup receiving fresh transfer of two cleavage embryos, mLP looked dramatically better (65.8% vs 36.4% clinical pregnancy) — but that finding doesn't survive multiple-comparison correction. Promising lead, not settled answer.

Summary

Multicenter RCT, 6 Chinese fertility centers. mLP arm: letrozole 5 mg/day for 5 days starting CD2 + gonadotropin from CD5. Control arm: gonadotropin from CD2. Both arms used dual trigger (hCG + GnRH-agonist).

Outcome	mLP	GnRH-ant	p
Cumulative live birth rate	24.5%	22.6%	0.991
Stim days	6.6	9.4	<0.0001
Endometrium at trigger (mm)	9.2	10.3	0.001
DOR + 2-cleavage fresh CPR	65.8%	36.4%	0.015 (adj. 0.150)
Repeat-cycle CPR	51.7%	23.3%	0.047

Proposed mechanism: letrozole sustains testosterone elevation during follicle growth, improves synchronization, and prevents the lining from over-maturing — keeping embryo timing and endometrial receptivity in sync for fresh transfer.

Relation to my history

I fit the enrollment criteria: age 40, AMH 1.30 ng/mL, AFC 6. My March 2026 Grace cycle was a GnRH-antagonist variant with two non-trial modifications:

Letrozole 5 mg CD3–7 was given the cycle before stim (Feb 8–12), not during stim as the trial tests.
Clomid 50 mg × 10 days was added during stim — not part of either trial arm.

Other gaps vs the trial: single trigger (Ovidrel only) instead of dual, endometrium 6.1 mm at trigger (well below trial average 10.3), and 3 cleavage embryos transferred instead of 1–2. β-hCG negative.

Confidence: how well each finding applies to me

Finding	Confidence	Note
I fit the trial population	High	Age qualifies alone; AMH and AFC borderline.
mLP and GnRH-ant give similar overall outcomes — either is a reasonable choice	High	Primary endpoint of a well-powered RCT.
mLP uses less drug over fewer days	High	Cost / logistics signal, p<0.0001.
Dual trigger is standard — single trigger at Grace was a gap	High	Both trial arms used dual. Confirm with CZ clinics.
mLP advantage for DOR + fresh 2-cleavage transfer (65.8% vs 36.4%)	Medium	Large effect but adjusted p=0.150 — doesn't survive correction.
mLP advantage for repeat cycles — relevant to my 2–3 cycle plan	Medium	Small subgroup, single trial. Direction consistent.
Zero LBR reported in the 6–7 mm endometrium subgroup matches my 6.1 mm	Medium	Direct numerical match but subgroup is tiny (n=13).
Prior-cycle letrozole priming (what I did) is equivalent to mLP	Low	Different intervention — letrozole had cleared before stim started.

Questions to raise with each CZ clinic

Have you considered letrozole co-administration during stim for my profile (borderline DOR, age 40, thin endometrium history)?
Will the trigger be dual (hCG + GnRH-agonist) or single?
If fresh day-3 transfer is planned, are two cleavage embryos standard?
If endometrium is <7 mm at trigger, is the contingency freeze-all and FET?